Aug 08, 2022 / 12:00PM GMT
Operator
Good morning, and welcome to the Karuna Therapeutics conference call. I'll now hand the call over to Alexis Smith, Director of Investor Relations.
Alexis Smith;Director of Investor Relations -
Hello, and thank you for joining our call today. This call will focus on the top line results from our Phase III EMERGENT-2 trial evaluating our lead investigational therapy, KarXT, in adult schizophrenia.
Before we begin, please note that this conference call will include forward-looking statements made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Please see Slide 2 of the accompanying presentation and our SEC filings for important risk factors that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements.
Steve Paul, Chief Executive Officer, President and Chairman of the Board, will begin today's presentation, followed by remarks from Steve Brannan, our Chief Medical Officer; and Andrew Miller, our Founder and Chief
Karuna Therapeutics Inc Phase 3 EMERGENT-2 Trial Topline Results- Conferene Call Transcript
Aug 08, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers